A Short Summary Of Tafinlar and Mekinist NDA Deficiencies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The clinical reviewer for both Tafinlar and Mekinist, Marc Theoret, presented a summary of problems with the “quality and integrity” of the NDAs: